Skip to main content
    C

    CNS Pharmaceuticals Inc (CNSP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.15
    +0.67 (+19.25%)

    Market Cap: $5.09M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    CNS Pharmaceuticals Inc (CNSP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CNS Pharmaceuticals (CNSP) has a market cap of $5.09M. Its share count is up 1798.93% from a year earlier. It holds $17.21M more cash than debt, 338.43% of its market cap.

    Total Valuation

    Market Cap$5.09M
    Latest price (Nov 17, 2026)$4.15

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 16, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 55.19% in the quarter ended Sep 30, 2026.

    Shares Outstanding10.61M
    Shares Change (YoY)+1798.93%
    Shares Change (QoQ)+55.19%

    Price Statistics

    The stock is down 39.86% over 52 weeks and trades 14.96% below its 50-day average.

    Beta (1Y)0.05
    52-Week Change-39.86%
    1-Month Change-16.83%
    3-Month Change-28.82%
    6-Month Change-13.18%
    5-Year Change-100.00%
    Total Return (1Y)-39.86%
    Total Return (3Y CAGR)-96.27%
    Total Return (5Y CAGR)-91.70%
    Return vs SPY (1Y)-49.85%
    Max Drawdown (1Y)-72.66%
    Max Drawdown (3Y)-100.00%
    Sharpe Ratio (1Y)-0.32
    Correlation with SPY (1Y)0.00
    50-Day Average$4.88
    200-Day Average$4.45
    52-Week Range$1.90 to $10.54
    RSI (14 Days)47.5
    Average Volume (20 Days)18.68K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 7.65x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio7.65x
    Quick Ratio7.65x
    Debt / Equity0.00x
    Interest Coverage-1019.01x

    Returns and Efficiency

    Return on equity is -101.75% and return on assets is -88.46% over the last 12 months.

    Return on Equity (ROE)-101.75%
    Return on Assets (ROA)-88.46%
    ROIC (5Y Average)-78.77%

    Scores

    CNSP has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit$2.90K
    Operating Income-$16.33M
    Pretax Income-$15.98M
    Net Income-$15.98M
    Reported EPS (TTM)-$18.07

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 86.99% of the $18.06M in total assets.

    Cash and Equivalents$17.21M
    Total Debt$0
    Net Cash$17.21M
    Net Cash Per Share$1.62
    Working Capital$15.69M
    Shareholder Equity$15.71M
    Book Value Per Share$1.48
    Total Assets$18.06M
    Total Liabilities$2.36M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$14.01M
    FCF Per Share-$9.61

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Dividends and Yields

    CNSP does not pay a dividend.

    Buyback Yield-49.29%
    Shareholder Yield-49.29%

    Stock Splits

    The last split was a 1-for-12 reverse split on Jul 22, 2025.

    Last Split DateJul 22, 2025
    Split TypeReverse split
    Split Ratio1:12

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CNSP

    What is CNSP's market cap?

    CNS Pharmaceuticals has a market cap of $5.09M.

    How many shares of CNSP are outstanding?

    CNS Pharmaceuticals has 10.61M shares outstanding. The count is up 1798.93% from a year earlier.

    Does CNSP pay a dividend?

    No. CNS Pharmaceuticals does not pay a dividend.

    How much debt does CNSP have?

    CNS Pharmaceuticals has $0 of total debt and $17.21M of cash and equivalents, a net cash position of $17.21M.